The treatment of classical Hodgkin lymphoma (cHL) in children is a story of success. Nowadays, more than 90% of patients are cured and overall survival is nearly 100% at 5years. Efforts have been made to avoid related effects of therapies; therefore, children are treated using different ...
The treatment of classical Hodgkin lymphoma (cHL) in children is a story of success. Nowadays, more than 90% of patients are cured and overall survival is nearly 100% at 5 years. Efforts have been made to avoid related effects of therapies; therefore, children are treated using different che...
Considerations for anti-PD1-based first-line treatment of Hodgkin lymphoma Anti-PD1-based first-line treatment holds great promise in classical Hodgkin lymphoma. The management of immune-related adverse events in the context of ti... PJ Broeckelmann - 《British Journal of Haematology》 被引量: ...
The successful treatment of Hodgkin's lymphoma is one of the most impressive achievements of modern medicine. Today more than 90 % of patients without fever, weight loss, or night sweats (B symptoms) are cured with optimal treatment, and 60–70 % of those with B symptoms are cured as ...
There are 785 clinical trials currently in progress to find the optimum treatment for each patient.References:Gospodarowicz MK et al, “The management of patients with limited-stage classical Hodgkin lymphoma”, Hematology Am Soc Hematol Educ Program. 2006: 253-8....
Although this is a report of a single case, cautious use of anti-TNF drugs is strongly recommended as they might cause lymphoma development even in AS. 展开 关键词: Non-Hodgkin’s lymphoma Etanercept Ankylosing spondylitis DOI: 10.1007/s00296-009-1265-0 被引量: 53 ...
Current Treatment Approaches for Mantle-Cell Lymphoma Mantle-cell lymphoma (MCL) is now recognized as a distinct clinicopathologic subtype of B-cell non-Hodgkin's lymphoma. Patients with MCL are typically olde... Witzig,E T. - 《Journal of Clinical Oncology》 被引量: 458发表: 2005年 Present ...
KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. Classical Hodgkin Lymphoma KEYTRUDA is ind...
- 《Annals of Oncology Official Journal of the European Society for Medical Oncology》 被引量: 31发表: 2013年 Risk of second malignancies in patients with early-stage classical Hodgkin's lymphoma treated in a modern era Second malignancies remain an issue affecting morbidity and mortality in long...
Since 1999, the data has been entered from the lymphoma multidisciplinary team meetings at the City Hospital (NCH). Survival after Hodgkin's disease treatment EM Bessell et al 532 All patients diagnosed at the three hospitals are discussed at this meeting. The cause of death was determined by...